Back to Trades
Total Value
$NaN
Filing Date
Mar 27, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Megiddo Dalia, Chief Development Officer, Director, reported $NaN of Nasus Pharma Ltd (NSRX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Nasus Pharma Ltd
- Ticker Symbol
- NSRX
- CIK
- 0002029039
Insider Information
- Name
- Megiddo Dalia
- Role
- Chief Development Officer, Director
Filing Details
- Filing Date
- Mar 27, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001493152-26-013386
- Form Type
- 3
Want live alerts when Megiddo Dalia trades again?
Download Insider Trades to track NSRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Dr. Dalia Megiddo, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.